已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps

医学 慢性鼻-鼻窦炎 鼻息肉 皮肤病科 内科学
作者
Anju T. Peters,Joseph K. Han,Peter W. Hellings,Enrico Heffler,Philippe Gevaert,Claus Bachert,Yingxin Xu,Chien‐Chia Chuang,Binod Neupane,Jérôme Msihid,Leda P. Mannent,Patricia Guyot,Siddhesh Kamat
出处
期刊:The Journal of Allergy and Clinical Immunology: In Practice [Elsevier BV]
卷期号:9 (6): 2461-2471.e5 被引量:69
标识
DOI:10.1016/j.jaip.2021.01.031
摘要

Among patients with chronic rhinosinusitis with nasal polyps (CRSwNP), randomized clinical trials (RCTs) of biologics, such as anti-interleukin-4/interleukin-13 (dupilumab) and anti-immunoglobulin E (omalizumab), have demonstrated efficacy compared with intranasal corticosteroids (INCS). However, no head-to-head RCTs exist between biologics.To perform an indirect treatment comparison (ITC) of the efficacy of biologics plus INCS versus placebo (INCS) as a common comparator.Embase, MEDLINE, and Cochrane were searched for RCTs of biologics in CRSwNP. Bucher ITCs were performed for outcomes at week 24: nasal polyp score (NPS) (range, 0-8), nasal congestion (NC) (range, 0-3), loss of smell (range, 0-3), University of Pennsylvania Smell Identification Test (range, 0-40), total symptom score (range, 0-12), 22-item sinonasal outcome test (range, 0-110), and responder analyses based on NPS or NC improvement of 1 point or greater.Assessment of trial design, baseline characteristics, and outcome measures suggested that ITC was feasible with four phase 3 RCTs: dupilumab SINUS-24 and SINUS-52 (NCT02912468/NCT02898454) and omalizumab POLYP 1 and POLYP 2 (NCT03280550/NCT03280537). In the intent-to-treat population, dupilumab had significantly greater improvements from baseline to week 24 versus omalizumab across key outcomes: NPS (least squares mean difference [95% confidence interval], -1.04 [-1.63 to -0.44]), NC (-0.35 [-0.60 to -0.11]), loss of smell (-0.66 [-0.90 to -0.42]), University of Pennsylvania Smell Identification Test (6.70 [4.67-8.73]), and total symptom score (-1.18 [-1.95 to -0.41]). Improvement in the 22-item sinonasal outcome test was greater in dupilumab versus omalizumab but was not statistically significant. Dupilumab patients were significantly more likely to achieve ≥1-point improvement in NPS (odds ratio [95% CI] = 3.58 [1.82-7.04]) and NC (2.13 [1.12-4.04]) versus omalizumab.Although ITCs have limitations, these results demonstrated that dupilumab had consistently greater improvements in key CRSwNP outcomes versus omalizumab at week 24.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
mengliu完成签到,获得积分10
1秒前
李健的粉丝团团长应助Li采纳,获得10
4秒前
NexusExplorer应助zhouleiwang采纳,获得10
7秒前
云上人完成签到 ,获得积分10
8秒前
wxh发布了新的文献求助10
9秒前
suxili完成签到 ,获得积分10
11秒前
12秒前
大观天下发布了新的文献求助10
15秒前
熊二浪完成签到,获得积分10
17秒前
Owen应助读书的时候采纳,获得10
19秒前
大模型应助wxh采纳,获得10
19秒前
21秒前
威武灵阳完成签到,获得积分10
22秒前
sunnn完成签到 ,获得积分10
22秒前
薯条一克完成签到 ,获得积分10
25秒前
郗妫完成签到,获得积分10
26秒前
深山何处钟声鸣完成签到 ,获得积分0
27秒前
欢呼的世立完成签到 ,获得积分10
27秒前
平常的羊完成签到 ,获得积分10
34秒前
未夕晴完成签到,获得积分10
36秒前
Atropine完成签到 ,获得积分10
39秒前
40秒前
40秒前
41秒前
明亮访烟完成签到 ,获得积分10
43秒前
zhouleiwang发布了新的文献求助10
44秒前
45秒前
荔枝完成签到 ,获得积分10
45秒前
忐忑的雪糕完成签到 ,获得积分10
47秒前
Cong发布了新的文献求助10
48秒前
SYLH应助小刘采纳,获得10
50秒前
jojo完成签到 ,获得积分10
53秒前
54秒前
广东第一深情完成签到,获得积分10
57秒前
灵巧的十八完成签到 ,获得积分10
58秒前
wxh发布了新的文献求助10
59秒前
桐桐应助zhouleiwang采纳,获得10
1分钟前
啊哈哈哈完成签到 ,获得积分10
1分钟前
小湛完成签到 ,获得积分10
1分钟前
菜根谭完成签到 ,获得积分10
1分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989989
求助须知:如何正确求助?哪些是违规求助? 3532034
关于积分的说明 11256053
捐赠科研通 3270900
什么是DOI,文献DOI怎么找? 1805105
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809216